Answers are grounded in this paper and cite their sources.
Many recombinant-protein drugs such as erythropoietin are now off patent, and the availability of generic versions of these drugs would reduce costs. The federal laws that simplify and expedite approval of generic forms of other drugs do not apply to recombinant-protein drugs. Congress is developing legislation to facilitate the approval of follow-on protein drugs.
No takes yet. Share an insight, caveat, or question.
Dudzinski et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: